What We Do
1 – TID
- Identify and validate structural proteins
- Characterize target druggability through in silico and experimental data
2 – F2H
FIELDS TO HIT
- Match targets with FIELDS real data
3 – HV
- Validate binding pocket and property enumeration
4 – H2L
HIT TO LEAD
- Iterative screening, Med-Chem tractability, and lead identification
5 – LO
- NCEs to synthesis
- SAR to lead selection
6 – CN
Precise: Our training set of real empirical/wet lab data allows us to cover the spectrum of protein/small molecule interactions to discover targetable hot spots, minimizing the “hit-and-miss” of traditional drug discovery.
Accelerated: Cutting-edge platform supported by decades of work and over 5 years of AI/ML development to discover new medicines with previously impossible speed and accuracy.
Validated: FIELDS™ is trained on hundreds of 3D structures, from PDB and DeepMind AlphaFold protein targets, screened against our IP rich proprietary fragment and NCE library.
Other Solid Tumors
IPF (D0D Funded)
Diseases – ALS/AD
Biolexis utilizes the FIELDS™ platform to discover and develop our own NCEs. Our pipeline projects are available for licensing or partnering.
NCE DISCOVERY AND DEVELOPMENT
FIELDS™ can discover and develop innovative, IP-rich NCEs targeting any class of proteins. Our training set of real empirical/wet lab data allows us to cover the spectrum of protein/small molecule interactions and discover targetable hot spots on target proteins. FIELDS™ takes you from simple concept to drugable NCEs in a fraction of the time.
Give us your most challenging protein target and we'll show you what FIELDS™ can do.